Dyadic International, Inc. (DYAI) is a biotechnology platform company, not an ETF, and it has very thin sell-side coverage. Only two attributable, individually identified analyst price targets were located. Craig-Hallum analyst Matthew Hewitt initiated coverage with a Buy rating and a $5 target on September 8, 2025, citing near-term commercialization catalysts for the company's C1 platform. H.C. Wainwright initiated (resumed) coverage with a Buy rating and a $3 target on October 23, 2025. The arithmetic mean of these two targets is $4, with a range of $3 to $5.
Several caveats apply. Both targets are more than a year old, and neither has been confirmed as current in recent months. Aggregators now show no meaningful live consensus target for the stock, and MarketBeat lists a Weiss Ratings downgrade in October 2026 with no current price target. A separate skeptical Seeking Alpha author has publicly floated a much lower $2 one-year objective, arguing the C1 platform has yet to prove commercial viability. This is not a formal analyst target, but it illustrates how wide the range of informed opinion has become. Because the two attributable targets are so old and the company's situation has deteriorated, the $4 figure should be read as historical analyst context rather than a live consensus.
As of the most recent session, DYAI traded near $0.35, near the bottom of a 52-week range of $0.33 to $1.60. The shares have fallen roughly 78% from their 52-week high and are down more than 50% over the trailing year. With a market capitalization of approximately $14–15 million, the stock sits firmly in micro-cap territory.
Moving from about $0.35 to the $4 target would require upside of roughly 1,000%, which must be characterized as a very large move rather than a modest or routine one. The gap between the current price and the historical targets reflects how dramatically the company's equity value has compressed since those targets were issued. Any path toward the target would require a fundamental repricing of the business driven by sustained revenue growth, licensing milestones, or a transformative partnership.
The core asset is Dyadic's C1 gene-expression platform, built on the fungus Thermothelomyces heterothallica, which is designed to produce commercial quantities of proteins and enzymes for pharmaceutical and industrial uses. Analysts who initiated coverage praised C1's potential cost and delivery advantages in biomanufacturing and pointed to partner-driven clinical and commercial catalysts. Trailing-twelve-month revenue was roughly $3.8 million, and the company has reported periods of strong year-over-year growth, which underpins the bull case that licensing and collaboration revenue can scale. If new partnerships, regulatory milestones, or larger licensing deals materialize, the equity could re-rate substantially from current depressed levels.
The obstacles are substantial. The company is unprofitable, with negative EPS (earnings per share) and negative book value per share. In its third quarter of 2026, it reported revenue of roughly $450,000, well short of the approximately $1.51 million consensus estimate, and an EPS of -$0.04 versus an expected -$0.03. Persistent cash burn raises the risk of future dilution, which would weigh on any per-share target. The stock also carries micro-cap liquidity risk, a beta near 1.1, and an unproven record of converting its platform into durable, high-value licensing revenue. If commercialization continues to lag, the shares could struggle to hold even current levels, making a return to $4 extraordinarily difficult.
The shares are trading just above the 52-week low of $0.33, which now acts as the most immediate support level. Below that, there is little established technical floor. To the upside, the stock faces a resistance zone near $0.40–$0.47, followed by the 50-day moving average near $0.42 and the 200-day moving average near $0.74. The round $1 level and the 52-week high of $1.60 are the next notable milestones. The $4 target sits far above every current technical level, meaning the shares would need to clear multiple resistance zones and re-establish a sustained uptrend before that objective became relevant.
Analyst price targets generally reflect a research horizon of about 12 months, though the two DYAI targets were issued in late 2025 and have not been refreshed. Investors should watch quarterly results and guidance, new or expanded C1 licensing and collaboration agreements, clinical-trial progress by partners, cash position and any equity offerings, and analyst ratings changes. For a stock this small, liquidity and dilution risk matter as much as fundamental progress. None of this constitutes a forecast that the target will or will not be reached.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual scanning allows. For a volatile micro-cap such as DYAI, automated signal tools can help contextualize short-term price action. Explore the AI Daily Buy/Sell Signals to see how the system is reading the current market environment.
The $4 target for Dyadic International is the average of two Buy-rated analyst targets ($3 and $5) issued in late 2025, and it sits roughly 1,000% above the recent price near $0.35. Reaching it would demand a very large move and a fundamental repricing of the business. The bull case hinges on the C1 platform's long-term potential and future partnership or licensing catalysts, while the bear case rests on persistent losses, a recent revenue miss, negative book value, dilution risk, and a shrinking market capitalization. With coverage now effectively dormant and a skeptical $2 view also in public circulation, the range of credible outcomes is unusually wide. Investors should monitor earnings, cash runway, and any new licensing developments rather than treat $4 as a near-term or guaranteed objective.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that DYAI and MDGL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DYAI and MDGL's prices will move in lockstep.
| Ticker / NAME | Correlation To DYAI | 1D Price Change % | ||
|---|---|---|---|---|
| DYAI | 100% | +6.01% | ||
| MDGL - DYAI | 29% Poorly correlated | +0.10% | ||
| VRAX - DYAI | 29% Poorly correlated | -2.64% | ||
| FATE - DYAI | 28% Poorly correlated | -9.32% | ||
| TAOX - DYAI | 27% Poorly correlated | -1.55% | ||
| AZTR - DYAI | 27% Poorly correlated | -2.47% | ||
More | ||||